Edition:
India

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

2.38USD
8:00pm IST
Change (% chg)

$0.01 (+0.42%)
Prev Close
$2.37
Open
$2.35
Day's High
$2.40
Day's Low
$2.35
Volume
952
Avg. Vol
25,109
52-wk High
$4.83
52-wk Low
$1.29

Chart for

About

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS... (more)

Overall

Beta: 0.96
Market Cap(Mil.): $67.53
Shares Outstanding(Mil.): 33.80
Dividend: --
Yield (%): --

Financials

  CRME.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.82 -- --
ROI: -53.51 14.84 14.38
ROE: -123.49 16.34 16.07

BRIEF-Cardiome Announces Amendment To Term Loan Agreement With CRG Managed Funds

* CARDIOME ANNOUNCES AMENDMENT TO TERM LOAN AGREEMENT WITH CRG-MANAGED FUNDS

07 Apr 2018

BRIEF-Cardiome Pharma - William Hunter, President & CEO, Justin Renz, CFO Purchased Total Of 210,000 Common Shares Of Co On TSX And Nasdaq On March 26

* CARDIOME PHARMA - WILLIAM HUNTER, PRESIDENT & CEO, JUSTIN RENZ, CFO PURCHASED TOTAL OF 210,000 COMMON SHARES OF CO ON TSX AND NASDAQ ON MARCH 26 Source text for Eikon: Further company coverage:

28 Mar 2018

BRIEF-Health Canada Accepts Cardiome's Xydalba For Review

* HEALTH CANADA ACCEPTS CARDIOME'S XYDALBA NEW DRUG SUBMISSION AND GRANTS PRIORITY REVIEW

22 Mar 2018

BRIEF-Cardiome Pharma To Pay $2.5 Mln Termination Fee To Cipher If Proposed Arrangement Not Completed

* CARDIOME PHARMA-TERMINATION FEE OF $2.5 MILLION (CAD) PAYABLE BY CO TO CIPHER IN CERTAIN CIRCUMSTANCES IF PROPOSED ARRANGEMENT NOT COMPLETED - SEC FILING‍​

21 Mar 2018

BRIEF-Cipher Pharmaceuticals And Cardiome Pharma Announce Strategic Transaction For Canadian Business Portfolio Of Cardiome

* CIPHER PHARMACEUTICALS AND CARDIOME PHARMA ANNOUNCE STRATEGIC TRANSACTION FOR CANADIAN BUSINESS PORTFOLIO OF CARDIOME

20 Mar 2018

BRIEF-Cardiome Reports Q4 Loss Per Share $0.24

* CARDIOME REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

14 Mar 2018

BRIEF-Cardiome Announces Expanded Label For Aggrastat In China

* CARDIOME ANNOUNCES EXPANDED LABEL FOR AGGRASTAT® IN CHINA INCLUDING NEW STEMI INDICATION AND HIGH DOSE BOLUS REGIMEN

23 Jan 2018

BRIEF-Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

* CARDIOME ANNOUNCES STRATEGIC LICENSING AGREEMENT TO COMMERCIALIZE AGGRASTAT IN RUSSIA

12 Dec 2017

BRIEF-Cardiome Q3 loss per share $0.20

* Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S

15 Nov 2017

BRIEF-Cardiome Pharma commercially launches Xydalba in Sweden, Finland and Republic Of Ireland​

* Cardiome Pharma - has initiated commercial launch of Xydalba (dalbavancin hydrochloride) in Sweden, Finland and Republic Of Ireland​ Source text for Eikon: Further company coverage:

30 Oct 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $127.08 -0.64
Pfizer Inc. (PFE.N) $36.35 -0.14
Novartis AG (NOVN.S) CHF77.28 -1.52
Bayer AG (BAYGn.DE) €99.60 -0.70
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €65.60 -0.21
AstraZeneca plc (AZN.L) 4,955.50 -9.00
GlaxoSmithKline plc (GSK.L) 1,407.40 -14.20
Gilead Sciences, Inc. (GILD.OQ) $74.13 -1.55
Boston Scientific Corporation (BSX.N) $28.97 +0.03

Earnings vs. Estimates